Abstract
Insulin glargine is a long-acting insulin analogues with senior course without effect and low intra-individual variability. ORIGIN study demonstrated its cardiovascular safety.
Insulin glargine in this study did not increase the risk of malignancy. Based on clinical experience has allowed any use of insulin glargine during pregnancy.
Currently tested formulations glargine insulin concentration of 300 U / ml, which exhibit reduced risk of hypoglycemia as compared to the standard concentration of 100 U / ml.